Evaluation of pleural fluid survivin and XIAP for the diagnosis of malignant pleural effusion

Tumor Biology

Volumn 33, Issue 5, 2012, Pages 1803-1810

  Li, Jian ^a   Li, Zhen Nan ^b   Bao, Qian Lei ^a   Ge, Li Ping ^a   Li, Xiao Qin ^a   Chen, Ping ^a  

^a AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Diagnosis; Malignant pleural effusion; Survivin; XIAP

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; MESSENGER RNA; SURVIVIN; TUMOR MARKER; X LINKED INHIBITOR OF APOPTOSIS;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; BREAST CANCER; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; LUNG ADENOCARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT PLEURA EFFUSION; PARAPNEUMONIA EFFUSION; PLEURA BIOPSY; PLEURA EFFUSION; PLEURA FLUID; PREDICTIVE VALUE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUBERCULOUS PLEURISY;

EID: 84868142935     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0439-7     Document Type: Article

References (41)

1. Marel M, Zrustova M, Stasny B, Light RW. The incidence of pleural effusion in a well-defined region: epidemiologic study in central Bohemia. Chest. 1993;104:1486-9.
2. Valdes L, Alvarez D, Valle JM, Pose A, SanJose E. The etiology of pleural effusions in an area with high incidence of tuberculosis. Chest. 1996;109:158-62.
3. Tassi GF, Cardillo G, Marchetti GP, Carleo F, Martelli M. Diagnostic and therapeutical management of malignant pleural effusion. Ann Ocol. 2006;17 suppl 2:ii 11-2.
4. Antony VB, Loddenkemper R, Astoul P, Boutin C, Goldstraw P, Hott J, et al. Management of malignant pleural effusion. Eur Respir J. 2001;18:402-19.
5. Maskell NA, Butland RJ. BTS guidelines for the investigation of a unilateral pleural effusion in adults. Thorax. 2003;58:8-17.
6. Nance KV, Shemer RW, Askin FB. Diagnostic efficacy of pleural biopsy as compared with that of pleural fluid examination. Mod Pathol. 1991;4:320-4.
7. Menzies R, Charbonneau M. Thoracoscopy for the diagnosis of pleural disease. Ann Intern Med. 1991;114:271-6.
8. Miédougé M, Rouzaud P, Salama G, Pujazon M-C, Vincent C, Mauduyt M-A, et al. Evaluation of seven tumor markers in pleural fluid for the diagnosis of malignant effusion. Br J Cancer. 1999;81:1059-65.
9. Porcel JM, Vives M, Esquerda A, Salud A, ChemD BP, Rodriguez-Panadero F. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusion. Chest. 2004;126:1757-63.
10. Lee JH, Chang JC. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer. Chest. 2005;128:2298-303.
11. Riantawan P, Sangsayan P, Bangpattanasiri K, Rojanaraweewong P. Limited additive value of pleural fluid carcinoembryonic antigen level in malignant pleural effusion. Respiration. 2000;67:24-9.
12. Garcia-Pachon E, Padilla-Navas I, Dosda D, Miralles-Llopis A. Elevated level of carcinoembryonic antigen in nonmalignant pleural effusion. Chest. 1997;11:643-7.
13. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 2003;22:8581-9.
14. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396:580-4.
15. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3:46-54.
16. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917-21.
17. Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C, et al. Analysis of human transcriptomes. Nat Genet. 1999;23:387-8.
18. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med. 2001;7:542-7.
19. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death protease. Nature. 1997;388:300-4.
20. Holcik M, Gibson H, Korneluk RG. XIAP: apoptotic brake and promising therapeutic target. Apoptosis. 2001;6:253-61.
21. Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS, Reed JC. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J. 1999;18:5242-51.
22. Hofmann HS, Simm A, Hammer A, Silber RE, Bartling B. Expression of inhibitors of apoptosis (IAP) proteins in non-small cell human lung caner. J Cancer Res Clin Oncol. 2002;128:554-60.
23. Krajewska M, Kim H, Kim C, Kang H, Welsh K, Matsuzawa S, et al. Analysis of apoptosis protein expression in early-stage colorectal cancer suggests opportunities for new prognostic biomarkers. Clin Cancer Res. 2005;11:5451-61.
24. Krajewska M, Krajewski S, Banares S, Huang X, Turner B, Bubendorf L, et al. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res. 2003;9:4914-21.
25. Liu SS, Tsang BK, Cheung AN, Xue WC, Cheng DKL, Ng TY, et al. Anti-apoptotic proteins, apoptotic and proliferative parameters and their prognostic significance in cervical carcinoma. Eur J Cancer. 2001;37:1104-10.
26. Kashkar H, Haefs C, Shin H, Hamilton-Dutoit SJ, Salvesen GS, Krönke M, et al. XIAP-mediated caspase inhibition in Hodgkin's lymphoma-derived B cells. J Exp Med. 2003;198:341-7.
27. Ferreira CG, van der Valk P, Span SW, Ludwig I, Smit EF, Kruyt FAE, et al. Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients. Clin Cancer Res. 2001;7:2468-74.
28. Seligson DB, Hongo F, Huerta-Yepez S, Mizutan Y, Miki T, Yu H, et al. Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence. Clin Cancer Res. 2007;13:6056-63.
29. Mizutani Y, Nakanishi H, Li YN, Matsubara H, Yamamoto K, Sato N, et al. Overexpression of XIAP expression in renal cell carcinoma predict a worse prognosis. Int J Oncol. 2007;30:919-25.
30. Wu M, Orta L, Gil J, Li G, Hu A, Durstein DE. Immunohistochemical detection of XIAP and P63 in adenomatous hyperplasia, atypical adenomatous hyperplasia, bronchioloalveolar carcinoma and well-differentiated adenocarcinoma. Mod Pathol. 2008;21:553-8.
31. Wu M, Sun Y, Li G, Desman G, Wang B, Gil J, et al. Immunohistochemical detection of XIAP in mesothelium and mesothelial lesions. Am J Clin Pathol. 2007;128:783-7.
32. Kleinberg L, Florenes VA, Silins I, Haug K, Trope CG, Nesland JM, et al. Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma. Cancer. 2007;109:228-38.
33. Lan CC, Wu YK, Lee CH, Huang Y-C, Huang C-Y, Tsai Y-H, et al. Increased survivin mRNA in malignant pleural effusion is significantly correlated with survival. Jpn J Clin Oncol. 2010;40:234-40.
34. Wang T, Qian X, Wang Z, Wang L, Yu L, Ding Y, et al. Detection of cell-free BIRC5 mRNA in effusion and its potential diagnostic value for differentiating malignant and benign effusion. Int J Cancer. 2009;125:1921-5.
35. Wu M, Yuan S, Szporn AH, Gan L, Shtilbans V, Burstein DE. Immunocytochemical detection of XIAP in body cavity effusions and washes. Mod Pathol. 2005;18:1618-22.
36. Lyons-Boudreaux V, Mody DR, Zhai J, Coffey D. Cytologic malignancy versus benignancy. How useful are the newer markers in body fluid cytology? Arch Pathol Lab Med. 2008;132:23-8.
37. Moussa O, Abol-Enein H, Bissada NK, Keane T, Ghoneim MA, Watson DK. Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer. J Urol. 2006;175:2312-6.
38. Kenney DM, Geschwindt RD, Kary MR, Linic JM, Sardesai NY, Li ZQ. Detection of newly diagnosed bladder cancer, bladder recurrence and bladder cancer in patients with hematuria using quantitative RT-PCR of urinary survivin. Tumor Biol. 2007;28:57-62.
39. Wu YK, Chen KT, Kuo YB, Huang YS, Chan EC. Quantitative detection of survivin in malignant pleural effusion for the diagnosis and prognosis of lung cancer. Cancer Lett. 2009;273:313-35.
40. Shen J, Pinkus GS, Deshpande V, Cibas ES. Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids. Am J Clin Pathol. 2009;131:516-23.
41. Passebosc-Faure K, Li G, Lambert C, Cottier M, Gentil-Perret A, Fournel P, et al. Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions. Clin Cancer Res. 2005;11:6862-7.